试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2010-04-13
Study of Optimal Posology of Gonadotrophins in Patients With Insufficient Ovarian Response Due to Age
编号:NCT00575302登记状态:入组前撤回企业 / 申办者:Centre Hospitalier Chretien
药物 / 成分:Gonal-f®: follitropin alpha、Gonal-f®: follitropin alpha
登记的停止原因(原文):36 cases were included and the 4 centers and they are unable to increase their recruitment to obtain the 400 cases necessary to reach statistical significance.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2010-04-08
Verapamil and Catamenial Epilepsy
编号:NCT00559169登记状态:入组前撤回企业 / 申办者:University Health Network, Toronto
药物 / 成分:verapamil hyrochloride
登记的停止原因(原文):protocol changed and a new study using verapamil in epilepsy will be started in the near future
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2010-03-16
Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension
编号:NCT00155714登记状态:入组前撤回企业 / 申办者:National Taiwan University Hospital
药物 / 成分:type-5 phosphodiesterase Inhibitor (Sildenafil)
登记的停止原因(原文):We can't obtained the test drug (Vadenafil) from Bayer. They decided not to carry out this trail in Taiwan. Therefore this trail has never been started.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2010-03-09
Juvista in the Non-surgical Improvement of Existing Scars
编号:NCT00821457登记状态:入组前撤回企业 / 申办者:Renovo
药物 / 成分:Juvista、Placebo、Juvista
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2010-03-02
Endothelial Function in Patients With Sickle Cell Anemia Before and After Sildenafil
编号:NCT00937144登记状态:入组前撤回企业 / 申办者:The Baruch Padeh Medical Center, Poriya
药物 / 成分:Viagra (Sildenafil)、placebo
登记的停止原因(原文):we didnt recieved the medicine
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2010-02-26
A Study to Investigate the Safety and Clinical Effect of Nexagon® to Treat Persistent Epithelial Defects
编号:NCT00821561登记状态:入组前撤回企业 / 申办者:OcuNexus Therapeutics, Inc.
药物 / 成分:Nexagon®、Nexagon® vehicle
登记的停止原因(原文):Withdrawn prior to recruitment for business reasons.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2010-02-26
Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen
编号:NCT00918450登记状态:入组前撤回企业 / 申办者:Abbott
药物 / 成分:ABT-263
登记的停止原因(原文):Sponsor has decided to not proceed with this study.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2010-02-24
Safety Study of Depakote Versus Lithium in African Americans With Bipolar Disorder
编号:NCT01075126登记状态:入组前撤回企业 / 申办者:Lawson, William B., M.D., PhD, DFAPA
药物 / 成分:Depakote、Lithium
登记的停止原因(原文):key investigator relocated.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2010-02-15
Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension
编号:NCT00453414登记状态:入组前撤回企业 / 申办者:Actelion
药物 / 成分:Iloprost Inhalation Solution (Ventavis)
登记的停止原因(原文):Withdrawn due to lack of enrollment
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2010-02-09
Combination Therapy for Neovascular Age Related Macular Degeneration
编号:NCT00447031登记状态:入组前撤回企业 / 申办者:Yonsei University
药物 / 成分:intravitreal bevacizumab and triamcinolone acetonide
登记的停止原因(原文):Insufficient patients who met inclusion criteria
查看官方原始记录 ↗